CAPE TOWN, SA / ACCESSWIRE / August 16, 2021 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) ("Wuhan" or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research, is pleased to announce the following corporate update:
M2Bio Sciences launches M2Bio Labs alongside the distinguished Bay Harbour Market in Hout Bay. This picturesque setting encompasses 7500 square feet which will house the following departments:
- Food Sciences - Test kitchen for the Food Technology Team to develop and refine its proprietary medicinal food and beverage lines, and for the creation of alternative proteins for sustainable agriculture and consumption. The space will be decked out with offices, a lab and a fully functioning industrial kitchen.
- Aromachology - Research and development lab focused on aromatherapy and cosmetics lines, for retail distribution under the Dr. AnnaRx brand.
- Sustainable Materials and Packaging - 3D Printing lab dedicated to the development of hemp and mycelium composites as alternatives to single-use plastics.
- Sensory Stimulation Hub - A space to study the influence of sensory stimuli on human behavior, and to examine the relationship between these stimuli and the individual's feelings and emotions.
"We take great pride and are very excited about the cutting-edge research being conducted at M2Bio Labs. Our findings will enable us to provide effective and innovative solutions for individuals on their wellness journey. This is a first of its kind development in Africa, advancing mental health treatments in a nonclinical environment using the arts and senses - sight (vision), hearing (auditory), smell (olfactory), taste (gustatory) and touch (tactile)." said M2Bio Sciences CEO Jeff Robinson
The newly appointed Johara Hartley, Managing Director, M2Bio Labs added: "I am a firm believer that everything you need is within you, and if you still cannot find it inside, it probably grows from the ground you're standing on. The space we are creating integrates technology, science and the arts in order to reboot neural pathways and ultimately improve the healthcare process, using holistic, alternative and progressive medicine. We plunge into the core human senses and bring the individual back to their roots, evolving their experience. As much as we work physically, we must do the internal work and that starts with the realignment of our fundamentals. The very definition of being alive is to be able to respond to stimuli, among factors like consumption, movement and growth. The world around us cannot stop, but we can choose to pause and dedicate time for our physical health and mental well-being. We are more than capable of responding fruitfully to physical, biological and environmental stressors, as the most up-to-date versions of ourselves.''
The M2Bio Labs space complements the corporate offices located in Woodstock, Cape Town.
About Wuhan General Group, Inc./ M2Bio Sciences, Inc
Wuhan General Group, Inc. (DBA M2Bio Sciences), through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids and psilocybin medical research that develops and commercializes a range of CBD and mushrooms-based products under Dr. AnnaRx™, Medspresso™ and Liviana™ brands. In addition, our research and clinical trials with psilocybin are aimed at new therapies that will help patients who suffer from alcohol addiction, mental illness and cardiovascular diseases. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research and emerging technologies. The Company is traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol "WUHN".
For further information:
Safe Harbour Statement - In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company's future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company's business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company's website. The Company disclaims any responsibility to update any forward-looking statements.
SOURCE: Wuhan General Group, Inc./M2Bio Sciences, Inc.